Why traditional financial due diligence fails for medtech investments — and how to assess the clinical, technical, commercial, and team dimensions that actually determine success.
Medical device investments fail in the boardroom long before they fail in the market. The M&A team analyzes the financials. The operations team kicks the tires on manufacturing. But somewhere between the PowerPoint and the term sheet, the clinical reality gets lost.
A cardiac monitoring startup with $2M in revenue looks attractive on paper. But what if the FDA pathway is 18 months slower than modeled? What if the predicate device strategy is vulnerable to a competitor's recent 510(k)? What if post-market surveillance data shows a higher complication rate than clinical trials suggested?
These aren't financial problems. They're clinical problems. And they destroy value faster than cost overruns or manufacturing delays.
The core issue: traditional due diligence frameworks were built for companies that sell software or consumables, not for companies whose products must navigate the FDA, prove clinical superiority, and compete for reimbursement. Medical devices operate under constraints that no other business model faces. Understanding those constraints — and how they translate into risk — requires expertise that most deal teams don't have.
This guide breaks down medical device due diligence into the four dimensions that actually matter: clinical risk, technical risk, commercial risk, and team execution. We'll walk through a practical framework that covers comprehensive proprietary categories of assessment, explain the most common pitfalls we see in deal teams, and show you how to structure a scorecard that identifies winners and flags the deals that will blow up two years into integration.
Most due diligence processes measure financial performance and operational efficiency. Medical device due diligence must measure something else: the probability that a device successfully navigates from where it is today to market adoption.
That journey has four critical components, each with distinct risks:
Can the company prove the device works to FDA and clinicians? Is the evidence base solid? Is the regulatory pathway clear?
Is the IP defensible? Can the device be manufactured at scale? Is the design mature enough for commercial production?
Is reimbursement clear? How big is the addressable market? What's the competitive landscape and pricing power?
Does the team have FDA experience? Do they understand the clinical market? Can they execute on their plan?
Clinical risk is where most non-medical deals fail to ask the right questions. Here's what you actually need to evaluate:
The FDA doesn't have one process — it has dozens. 510(k), Premarket Approval (PMA), Breakthrough Device, Expedited Review, De Novo — each pathway has different requirements, timelines, and success rates.
The core question: Does the company have a clear 510(k) pathway, or are they relying on a Breakthrough Device designation that might not materialize?
A company building a Class II catheter with an obvious predicate device can move through 510(k) in 3-6 months. A company building a novel surgical robot hoping for a Breakthrough Device designation could wait 18-36 months for a decision.
Probe on:
Every device needs clinical evidence. The question is: how much, and how strong?
A diagnostic device might need 500 patient samples. A therapeutic device might need a 300-patient randomized controlled trial. A cardiology device will need years of post-market surveillance data.
Probe on:
Clinical superiority doesn't mean statistical significance — it means competitive differentiation from the perspective of a hospital, surgeon, or patient.
A new diagnostic test that is 2% more accurate than the current standard won't drive adoption. A diagnostic test that is 50% faster, requires less sample prep, and costs 30% less might.
Probe on:
Technical risk is where device engineering, IP, and manufacturing converge. A great device idea can fail if the IP is weak or the manufacturing scale-up is underestimated.
In medtech, IP is often overvalued. A patent that looks solid in isolation can be vulnerable to design-around or design-ahead strategies by competitors.
The core questions:
A device company with 8 patents looks impressive until you realize 6 are process patents (easy to design around) and 2 are composition patents (already licensed from a university). The real IP strength comes from 3 issued utility patents on the core mechanism and 5 years of trade secret manufacturing know-how that would take a competitor 18 months to reverse-engineer.
There's a spectrum between "we have a prototype that works on the bench" and "we can manufacture 10,000 units per month at cost." Many device companies claim to be at manufacturing readiness when they're actually at prototype stage.
Probe on:
Scaling device manufacturing is not linear. A device that costs $500 to manufacture at 100 units/month might cost $150 at 10,000 units/month — or it might still cost $400 if the design doesn't scale.
Probe on:
The best clinical device fails if doctors won't use it, hospitals won't buy it, or payers won't reimburse it. Commercial risk is where deals lose the most value post-acquisition.
This is the category that kills more device deals than any other. A device might be FDA-cleared and clinically superior, but if Medicare doesn't reimburse it or only reimburses at $2,000 when the company needs $5,000 to break even, the business is broken.
Reimbursement has three components:
Probe on:
Device companies often use "total addressable market" (TAM) calculations that are disconnected from reality. A device addressing a $10B market might only capture 0.5% of that market if adoption is slow.
Probe on:
The device market is moving fast. What looks like a white space today might have three competitors by the time your device launches.
Probe on:
The best clinical and commercial strategy fails with the wrong team. Device execution requires specific expertise that's rare.
Has the CEO or CTO led an FDA submission before? Have they won? Have they lost and recovered?
Regulatory experience is one of the strongest predictors of execution success. A team that's submitted three 510(k) applications knows the gotchas. A team on their first submission will lose 6 months to a surprise FDA question.
Probe on:
Device companies need clinical advisors and trial sites. These relationships typically come from the CEO or CTO's network.
Probe on:
Great devices fail with poor sales strategy. Conversely, devices with modest clinical advantages can win if the sales team understands hospital economics and surgeon workflows.
Probe on:
Scaling a device company requires discipline. Supply chain, quality, regulatory compliance, financial management — these aren't sexy, but they're what separate winners from companies that burn through capital.
Probe on:
Rather than a single score, a rigorous medical device due diligence process evaluates across comprehensive proprietary categories spanning multiple assessment domains. Each category is independently scored, then aggregated into a composite risk profile.
The framework is designed to identify deals that look attractive on paper but hide critical risks — and to flag underappreciated opportunities where strong execution teams can overcome clinical or commercial headwinds.
Each category is scored on a scale that combines quantitative data (timelines, clinical evidence, manufacturing yields) with qualitative assessment (management capability, competitive positioning, risk mitigation).
The result: a device scorecard that identifies the actual probability of commercial success — not just financial attractiveness.
A device company showing $2M in revenue with 40% YoY growth looks like a winner. But if that revenue comes from a single hospital system (not FDA-cleared) or from a clinical trial (not commercial), the growth won't continue post-launch.
What to do: Separate clinical revenue from commercial revenue. Validate that growth is replicable and sustainable.
Many companies claim they'll pursue a 510(k) based on a predicate device that's 15 years old and from a now-defunct competitor. Or they plan to use a predicate device that's functionally quite different, setting up an FDA rejection.
What to do: Meet with the company's regulatory advisors. Validate the predicate device strategy with a regulatory consultant outside the company.
Reimbursement isn't automatic post-FDA clearance. It's a separate process that can add 18-24 months to commercialization. Many deal teams acknowledge this but don't account for it in financial projections.
What to do: Build reimbursement risk into the model. Scenario-plan for late reimbursement or lower-than-expected reimbursement rates.
A device that costs $300 to manufacture at 500 units/month might cost $600 if something goes wrong with scale-up (supplier issues, yield problems, design rework). Most deal teams underestimate this risk.
What to do: Conduct a detailed manufacturing assessment. Map out the scale-up plan with actual supplier quotes and yield data.
Clinical trials slip. FDA reviews take longer than expected. Regulatory meetings are rescheduled. Yet companies consistently project clinical timelines that are 20-30% aggressive vs. industry norms.
What to do: Benchmark timelines against comparable devices. Build in contingency. Understand the company's track record on past timelines.
A device might have a KOL on the advisory board who publicly endorses it. But will that KOL actually drive adoption among their peers? Will surgeons use the device in their practice?
What to do: Conduct independent interviews with KOLs. Validate genuine enthusiasm vs. advisory board politeness.
The Vantage Score was built by physicians and biomedical engineers who've done deal due diligence professionally. We've seen the gaps in traditional financial analysis. We've seen deals that looked great fall apart because nobody asked the right clinical questions. And we've seen strong devices fail because reimbursement strategy was an afterthought.
The Vantage Score consolidates our proprietary multi-category framework into a single risk assessment that covers:
The result is a score that separates marketing hype from clinical reality — giving you and your team the data you need to make confident investment decisions.
Download and customize this checklist for your next medical device due diligence process.